Eli Lilly and (LLY)
NYSE: LLY
· Real-Time Price · USD
724.39
-0.15 (-0.02%)
At close: Sep 29, 2025, 11:14 AM
Eli Lilly and Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | Dec 31, 2012 | Sep 30, 2012 | Jun 30, 2012 | Mar 31, 2012 | Sep 30, 2011 | Jun 30, 2011 | Mar 31, 2011 | Sep 30, 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiometabolic Health Revenue | 11.34B | 9.21B | 7.41B | 7.51B | 834M | 986.9M | 928.5M | 777.8M | 866.4M | 796.5M | 748.1M | 1B | 785.4M | 613.9M | 627.1M | 548.3M | 585.8M | 454.6M | 456.1M | 334.7M | 966.9M | 861.3M | 922.6M | 759M | 887.9M | 869.9M | 893.7M | 964.4M | 1.48B | 1.88B | 2B | 1.85B | 2.03B | 1.82B | 1.82B | 1.9B | 2.49B | 2.65B | 2.41B | 2.25B |
| Cardiometabolic Health Revenue Growth | +23.18% | +24.32% | -1.43% | +801.03% | -15.49% | +6.29% | +19.38% | -10.23% | +8.78% | +6.47% | -25.55% | +27.95% | +27.94% | -2.10% | +14.37% | -6.40% | +28.86% | -0.33% | +36.27% | -65.38% | +12.26% | -6.64% | +21.55% | -14.52% | +2.07% | -2.66% | -7.33% | -35.05% | -20.94% | -6.31% | +8.42% | -8.98% | +11.86% | -0.48% | -4.16% | -23.48% | -6.25% | +10.34% | +7.06% | n/a |
| Immunology Revenue | 1.26B | 1.09B | 1.19B | 1.08B | 552.5M | 1.77B | 387.2M | 360.5M | 433.8M | 459.5M | 471.9M | 526.7M | 597.1M | 538.9M | 470.7M | 422.5M | 463.5M | 426.7M | 452.7M | 393.1M | 721.7M | 724.5M | 763.9M | 725.3M | 868.5M | 882.4M | 858.4M | 764.3M | 874.4M | 821.8M | 808.1M | 764.2M | 839.2M | 791.7M | 846.8M | 803.9M | 817.8M | 825.8M | 839.9M | 980.3M |
| Immunology Revenue Growth | +15.40% | -8.24% | +9.54% | +95.91% | -68.75% | +356.64% | +7.41% | -16.90% | -5.59% | -2.63% | -10.40% | -11.79% | +10.80% | +14.49% | +11.41% | -8.85% | +8.62% | -5.74% | +15.16% | -45.53% | -0.39% | -5.16% | +5.32% | -16.49% | -1.58% | +2.80% | +12.31% | -12.59% | +6.40% | +1.70% | +5.74% | -8.94% | +6.00% | -6.51% | +5.34% | -1.70% | -0.97% | -1.68% | -14.32% | n/a |
| Neuroscience Revenue | 344M | 272.1M | 469M | 487M | 2.08B | 1.75B | 1.67B | 1.36B | 1.4B | 1.48B | 1.45B | 1.51B | 1.64B | 1.44B | 1.33B | 1.27B | 1.2B | 1.15B | 1.2B | 1.01B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Neuroscience Revenue Growth | +26.42% | -41.98% | -3.70% | -76.57% | +18.97% | +4.55% | +23.23% | -2.84% | -5.41% | +1.46% | -3.47% | -7.89% | +13.27% | +8.28% | +5.11% | +5.58% | +4.72% | -4.16% | +18.22% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Oncology Revenue | 2.41B | 1.95B | 2.56B | 2.46B | 241.9M | 276.1M | 314.6M | 275.3M | 746M | 494.7M | 1.92B | 637.7M | 712.9M | 1.24B | 526.4M | 481M | 640.1M | 303.5M | 323.5M | 421.6M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Oncology Revenue Growth | +23.93% | -23.81% | +4.00% | +916.04% | -12.39% | -12.24% | +14.28% | -63.10% | +50.80% | -74.27% | +201.55% | -10.55% | -42.64% | +136.11% | +9.44% | -24.86% | +110.91% | -6.18% | -23.27% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Product, Total Revenue | 201.5M | 212.9M | 262.8M | 207.6M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Product, Total Revenue Growth | -5.35% | -18.99% | +26.59% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China Revenue | 465.9M | 450.8M | 429.2M | 459.9M | 395.1M | 376.2M | 377.2M | 390.8M | 399M | 372.7M | 350.8M | 343.4M | 352.1M | 406.5M | 376.4M | 400.3M | 522.5M | 362.2M | 320.7M | 289.1M | 239.8M | 267.3M | 1.01B | 923.4M | 928.2M | 900.3M | 1.09B | 1.02B | 1.09B | 3.15B |
| China Revenue Growth | +3.35% | +5.03% | -6.68% | +16.40% | +5.02% | -0.27% | -3.48% | -2.06% | +7.06% | +6.24% | +2.15% | -2.47% | -13.38% | +8.00% | -5.97% | -23.39% | +44.26% | +12.94% | +10.93% | +20.56% | -10.29% | -73.62% | +9.71% | -0.52% | +3.10% | -17.27% | +7.00% | -6.76% | -65.43% | n/a |
| Europe Revenue | 2.57B | 2.39B | 2.45B | 1.63B | 1.4B | 1.44B | 1.34B | 2.57B | 1.18B | 1.09B | 1.07B | 1.06B | 1.1B | 1.07B | 1.15B | 1.1B | 1.21B | 1.32B | 1.21B | 1.05B | 873M | 1.06B | 709.2M | 641.5M | 653.2M | 543.7M | 6.33B | 3.6B | 3.75B | 1.04B |
| Europe Revenue Growth | +7.77% | -2.42% | +50.34% | +16.00% | -2.57% | +7.71% | -47.92% | +118.12% | +7.95% | +1.54% | +1.70% | -4.06% | +3.17% | -6.96% | +4.42% | -9.19% | -8.43% | +9.46% | +15.31% | +19.90% | -17.72% | +49.61% | +10.55% | -1.79% | +20.14% | -91.40% | +75.48% | -3.91% | +262.39% | n/a |
| Japan Revenue | 521M | 402.2M | 559.2M | 429.1M | 462.7M | 363.9M | 439M | 390.8M | 455.6M | 387.2M | 395M | 487.7M | 454.4M | 410.2M | 534.8M | 595M | 665.4M | 571.8M | 664M | 660.1M | 666.7M | 592.3M | 3.52B | 3.06B | 3.25B | 2.89B | 664.8M | 608.8M | 664.3M | 555.8M |
| Japan Revenue Growth | +29.54% | -28.08% | +30.32% | -7.26% | +27.15% | -17.11% | +12.33% | -14.22% | +17.67% | -1.97% | -19.01% | +7.33% | +10.78% | -23.30% | -10.12% | -10.58% | +16.37% | -13.89% | +0.59% | -0.99% | +12.56% | -83.17% | +15.00% | -5.91% | +12.51% | +334.84% | +9.20% | -8.35% | +19.52% | n/a |
| Non-Us Revenue | 1.18B | 997.4M | 1.06B | 1.11B | 1.21B | 892.9M | 744.3M | 780.3M | 748.5M | 673.1M | 822.8M | 632M | 645.7M | 751.5M | 765.6M | 689.4M | 638.1M | 609.1M | 4.59B | 3.16B | 3.14B | 3.33B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Non-Us Revenue Growth | +18.52% | -6.28% | -3.97% | -8.12% | +35.08% | +19.97% | -4.61% | +4.25% | +11.20% | -18.19% | +30.19% | -2.12% | -14.08% | -1.84% | +11.05% | +8.04% | +4.76% | -86.74% | +45.32% | +0.53% | -5.53% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| United States Revenue | 10.81B | 8.49B | 9.03B | 7.81B | 7.84B | 5.69B | 6.46B | 5.37B | 5.53B | 4.44B | 4.66B | 4.42B | 3.93B | 5.17B | 5.18B | 3.99B | 3.7B | 3.94B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| United States Revenue Growth | +27.38% | -6.01% | +15.59% | -0.28% | +37.59% | -11.79% | +20.25% | -2.95% | +24.69% | -4.77% | +5.35% | +12.38% | -23.96% | -0.03% | +29.73% | +7.70% | -6.02% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 2.65B | 2.36B | 2.31B | 1.98B | 2B | 1.84B | 1.81B | 1.69B | 1.81B | 1.63B | 1.55B | 1.52B | 1.53B | 1.46B | 1.52B | 1.51B | 1.61B | 1.5B | 1.5B | 1.46B | 1.41B | 1.5B | 1.65B | 1.36B | 1.54B | 1.46B | 1.79B | 1.39B | 1.43B | 1.28B | 2.29B | 1.51B | 1.67B | 1.5B | 1.79B | 1.57B | 1.62B | 1.47B | 1.8B | 1.58B | 1.64B | 1.52B |
| Selling, General, and Administrative Revenue Growth | +12.08% | +2.32% | +16.34% | -0.92% | +9.08% | +1.46% | +7.18% | -6.71% | +10.80% | +5.36% | +1.87% | -0.59% | +4.52% | -3.61% | +0.94% | -6.77% | +7.45% | +0.40% | +2.85% | +3.00% | -6.13% | -8.57% | +21.03% | -11.48% | +5.15% | -18.53% | +28.60% | -2.52% | +11.55% | -44.09% | +51.46% | -9.09% | +10.74% | -15.95% | +14.35% | -3.53% | +10.09% | -18.04% | +14.13% | -3.65% | +7.34% | n/a |
| Research and Development Revenue | 3.34B | 2.73B | 3.02B | 2.73B | 2.71B | 2.52B | 2.56B | 2.41B | 2.36B | 1.99B | 2B | 1.8B | 1.78B | 1.61B | 1.96B | 1.71B | 1.66B | 1.67B | 1.84B | 1.47B | 1.39B | 1.39B | 1.58B | 1.38B | 1.4B | 1.23B | 1.45B | 1.28B | 1.27B | 1.11B | 1.47B | 1.34B | 1.27B | 1.26B | 1.45B | 1.24B | 1.34B | 1.22B | 1.44B | 1.14B | 1.17B | 1.04B |
| Research and Development Revenue Growth | +22.04% | -9.56% | +10.55% | +0.84% | +7.47% | -1.56% | +6.38% | +2.23% | +18.71% | -0.54% | +10.70% | +1.18% | +10.67% | -17.83% | +14.90% | +3.04% | -1.02% | -9.03% | +25.43% | +5.41% | -0.14% | -11.97% | +14.52% | -1.52% | +13.95% | -15.36% | +13.50% | +0.78% | +14.76% | -24.82% | +9.94% | +5.34% | +1.10% | -13.26% | +17.32% | -7.45% | +9.41% | -15.45% | +26.31% | -2.23% | +12.53% | n/a |